T. Rowe Price reports 5.3% stake in MoonLake

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 4,280,624 shares of MoonLake Immunotherapeutics common stock on a Schedule 13G. This position represents 5.3% of the outstanding common stock.

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. reported beneficial ownership of 4,280,624 shares of MoonLake Immunotherapeutics common stock on a Schedule 13G. This position represents 5.3% of the outstanding common stock. T. Rowe Price has sole voting power over 4,111,122 shares and sole dispositive power over 4,280,624 shares, with no shared voting or dispositive power. The firm states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.

Key Figures

Shares beneficially owned: 4,280,624 shares Percent of class: 5.3% Sole voting power: 4,111,122 shares +1 more

4 metrics

Shares beneficially owned 4,280,624 shares Amount beneficially owned by T. Rowe Price Investment Management, Inc.

Percent of class 5.3% Percentage of MoonLake Immunotherapeutics common stock class

Sole voting power 4,111,122 shares Shares over which T. Rowe Price has sole power to vote

Sole dispositive power 4,280,624 shares Shares over which T. Rowe Price has sole power to dispose

Key Terms

beneficially owned, sole voting power, sole dispositive power, Schedule 13G

4 terms

beneficially owned financial

"Amount beneficially owned: 4280624"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole power to vote or to direct the vote: 4111122"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 4280624"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"T. Rowe Price Investment Management, Inc. 2 |"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in MoonLake Immunotherapeutics (MLTX) does T. Rowe Price report on this Schedule 13G?

T. Rowe Price Investment Management, Inc. reports beneficial ownership of 4,280,624 shares of MoonLake Immunotherapeutics common stock, representing 5.3% of the class, according to the Schedule 13G filing.

How much voting power does T. Rowe Price have in MoonLake Immunotherapeutics (MLTX)?

T. Rowe Price reports sole voting power over 4,111,122 shares of MoonLake Immunotherapeutics common stock and no shared voting power, based on the ownership details in the Schedule 13G.

What dispositive power over MoonLake (MLTX) shares does T. Rowe Price report?

T. Rowe Price reports sole dispositive power over 4,280,624 shares of MoonLake Immunotherapeutics common stock and no shared dispositive power, indicating sole authority to direct the disposition of these shares.

Does T. Rowe Price admit beneficial ownership of MoonLake (MLTX) shares in this filing?

No. T. Rowe Price states that the filing shall not be construed as an admission that it is the beneficial owner of the referenced securities and that such beneficial ownership is expressly denied.

What class of MoonLake Immunotherapeutics (MLTX) securities is covered and what is the CUSIP?

The reported position covers common stock of MoonLake Immunotherapeutics, identified by CUSIP 61559X104, as disclosed in the Schedule 13G ownership section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 10:41 AM Accepted by SEC EDGAR 08/14/2026 - 10:39 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

MOONLAKE IMMUNOTHERAPEUTICS

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

61559X104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 61559X104

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,111,122.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,280,624.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,280,624.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MOONLAKE IMMUNOTHERAPEUTICS
(b)	Address of issuer's principal executive offices: DORFSTRASSE 29, ZUG, V8, 6300
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 61559X104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4280624
(b)	Percent of class: 5.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4111122
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4280624
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	08/14/2026